Ibogaine is a hallucinogen from West Africa that some researchers believe could treat opioid addiction and PTSD (post-traumatic stress disorder) in veterans. The National Defense Authorization Act (NDAA) is Congress's annual defense spending bill—it passes every year with bipartisan support and often includes health research provisions. A provision to study ibogaine for veterans could slip into this bill because: (1) veteran suicide is a bipartisan concern both parties care about, (2) the Trump administration has signaled openness to psychedelic research, and (3) the NDAA is a reliable vehicle for getting things through Congress.
Trump Executive Order establishing executive branch support for ibogaine veteran research removes the primary Republican floor-vote obstacle. Veteran suicide statistics are a durable bipartisan floor speech weapon. The NDAA vehicle is the most viable pathway given standalone bill crowding. Prior NDAA cycles have included psychedelic research provisions (FY2024 included MDMA/psilocybin study mandates). Resolves on official House co-sponsorship list published by Clerk of the House.